NAUT
Nautilus Biotechnology, Inc.
Next earnings Jul 29, 2026 · consensus $-0.14 EPS
Last earnings +0.8% on 2026-04-28
$2.27▲ +217.62%
over 1Y
L $0.64EODHDH $3.95
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today—
1W-0.4%
1M-6.6%
3M-39.9%
YTD+18.8%
1Y+217.6%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 8 analysts
Buy
Conservative balance sheet (liabilities/equity 0.22x).
Nautilus Biotechnology, Inc. shows limited reported revenue, and -37.6% ROE.
Sources: SEC EDGAR (CIK 0001808805, latest 10-Q filed 2026-04-28) · as of 6/26/2026, 6:37:13 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.